Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047770 · ClinicalTrials.gov registry record · Phase 3
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,013
- Enrollment target
NCT05047770 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,013 participants.
The verdict
NCT05047770, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,013 participants
- Enrollment target
Study Summary
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy adults 18 YOA and older, when administered sequentially or co-administered with Moderna's mRNA-1273 booster vaccination against COVID-19.
Interventions
- BIOLOGICAL mRNA-1273
- BIOLOGICAL HZ/su
- COMBINATION_PRODUCT Flu D-QIV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,013 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05047770
The ClinicalTrials.gov registry entry for NCT05047770 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,013 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which mRNA-1273 is the first listed.
NCT05047770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05047770 about?
NCT05047770 is a clinical study titled "A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine". The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy adults 18 YOA and older, ...
What is the current status of trial NCT05047770?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,013 participants. The study started on 2021-10-07. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT05047770?
The interventions under investigation include: mRNA-1273 (BIOLOGICAL), HZ/su (BIOLOGICAL), Flu D-QIV (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05047770?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.